L. Naya Ríos

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.

I. Muñoz Pousa, I. Rodríguez Constenla, J. M. Prieto González, 2020, Neurologia.

Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group.

J. Kulisevsky, P. Martínez-Martín, P. Pástor, 2021, Journal of Parkinson's disease.

Predictors of Loss of Functional Independence in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group

J. Kulisevsky, P. Martínez-Martín, P. Pástor, 2021, Diagnostics.

Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up

J. Kulisevsky, P. Martínez-Martín, P. Pástor, 2021, Diagnostics.